Agios制药 AGIO 深 沪
等待开盘 02-07 09:30:00 美东时间
26.52
-0.050
-0.19%
华盛通- 最 高30.0399
- 今 开27.03
- 成交量 73.57万股
- 最 低 24.44
- 昨 收 26.57
- 总市值 145.30万
- 52周最高 46.00
- 市盈率 静 --
- 换手率 1342.87%
- 52周最低 22.24
- 委 比 57.05%
- 总股本 5.48万
- 历史最高 138.85
- 量 比 1.11
- 振 幅 21.08%
- 历史最低 1.10
- 每 手 1
- 风险率 5.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approves Agios Drug For Thalassemia-Associated Anemia
FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.
2025-12-24 20:31
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
U.S. stocks traded mixed midway through trading, with the Dow Jones index falli...
2025-11-20 01:58
Earnings Outlook For Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) is gearing up to announce its quarterly ear...
2025-10-30 03:02
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals announces its management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 8:40 a.m. ET. The presentation will be webcast live on the company's Investors website, with a replay available for two weeks. Agios is a leader in PK activation and develops therapies for rare diseases, including PK deficiency and other hematologic conditions.
2025-05-28 11:00
RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target
RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and maintains $55 price target.
2024-09-19 21:08
